Sign in Subscribe
Pediatrics

Prednisone Response in Pediatric Acute Lymphoblastic Leukemia: A Multicenter Study

Strategic Insights

— 1 min read

Recent research has shed new light on the role of prednisone response in pediatric acute lymphoblastic leukemia (ALL). A study published in the Annals of Hematology has demonstrated that while prednisone response (PR) remains a key early treatment indicator, its independent prognostic significance has decreased with the advent of minimal residual disease (MRD)-guided risk assessment. The study analyzed clinical data from 2,979 pediatric patients primarily diagnosed with ALL and found that children with a poor prednisone response (PPR) exhibited multiple high-risk clinical features and had a poorer prognosis than those with a good prednisone response (GPR).

Key Takeaways:

  • Prednisone response remains a key early treatment indicator in pediatric acute lymphoblastic leukemia (ALL).
  • However, its independent prognostic significance has waned with the advent of minimal residual disease (MRD)-guided risk assessment.
  • The study analyzed clinical data from 2,979 pediatric patients primarily diagnosed with ALL, with 2,649 categorized as GPR and 330 as PPR.
  • Children in the PPR group exhibited multiple high-risk clinical features and had a poorer prognosis than those in the GPR group.
  • Multivariate Cox regression analysis revealed that days 15 and 33 MRD had a stronger predictive value than prednisone response.
  • Prednisone response showed strong predictive value for MRD positivity on both Day 15 and Day 33.
  • The findings support the contextual use of PR as a practical surrogate for MRD in resource-limited settings.
  • The study suggests the need to reconsider the role of PR in modern risk-adapted treatment strategies.

Statistics:

  • 2,979 pediatric patients were included in the study.
  • 2,649 patients were categorized as GPR.
  • 330 patients were categorized as PPR.
  • Days 15 and 33 MRD had a stronger predictive value than prednisone response (64.2% vs. 53.1%).
  • Prednisone response showed strong predictive value for MRD positivity on both Day 15 (85.1%) and Day 33 (78.5%).

Sources:

  • A multicenter study on the prognostic value of prednisone response in pediatric acute lymphoblastic leukemia. Annals of Hematology, 2025.
  • Published by Springer, One New York Plaza, Suite 4600, New York, Ny, United States.
  • Contact Yun-Yan He, Dept. of Pediatrics, First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China for additional information.

Read more